Biotech

T2 Biosystems (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, is announcing the release of two new peer-reviewed publications that demonstrate the superior performance of the T2Candida® Panel over blood culture and the capability of the T2Sepsis Solution™ to enable faster targeted therapy for patients. As quoted in …

T2 Biosystems (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, is announcing the release of two new peer-reviewed publications that demonstrate the superior performance of the T2Candida® Panel over blood culture and the capability of the T2Sepsis Solution™ to enable faster targeted therapy for patients.

As quoted in the press release:

In a 14 center study called “DIRECT2,” one of the sites was led by investigators at the University of Pittsburgh Medical Center who published in the journal Clinical Infectious Diseases that strong data demonstrates the T2Candida Panel’s substantial advantages over blood culture for identifying Candida infections. The study also demonstrates the ability of the T2Candida Panel to identify clinically important infections missed by blood culture, while dramatically shortening the time to treat an infection with targeted therapy.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1809.91+3.04
Silver19.89-0.37
Copper3.61-0.10
Palladium1965.07+43.06
Platinum891.26-5.74
Oil108.46+2.70
Heating Oil3.96+0.13
Natural Gas5.620.00

DOWNLOAD FREE REPORTS

×